Reach Us +1-217-403-9671
Cancer Characteristics That May Compromise Drug Efficacy | 19797
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

5th World Congress on Bioavailability and Bioequivalence Pharmaceutical R&D Summit

Georg F Weber
ScientificTracks Abstracts: J Bioequiv Availab
DOI: 10.4172/0975-0851.S1.017
I n the first-line defense against cancer, the gradual replacement of conventional chemotherapy with molecularly targeted agents has opened the possibility to tailor drug treatments to particular tumors. However, this transition necessitates the characterization of the molecular lesions that are causative for the transformation of healthy cells into cancerous cells, because drugs need to be matched with the underlying carcinogenic defect to be effective. Two additional caveats, caused by unique genetic changes in the primary tumors and in their metastases, can affect drug transport and metabolism and need to be taken into consideration. ? We performed a comprehensive molecular analysis of a recurrent sarcoma with the aim of supporting treatment decisions. The investigation identified a likely culprit for the disease in a point mutation within FAF1, which may cause a loss of apoptotic function consecutive to transforming DNA damage. The associated upregulation of gene products that regulate migration and invasion, as well as gene products for extracellular matrix molecules and their modulators, reflected the invasive nature of this cancer. Of note, the RNA levels for genes that regulate transport and metabolism were extensively skewed in the tumor tissue as compared to muscle and bone. While the study informed on potential challenges to chemotherapy posed by drug transport and drug metabolism pharmacogenetics, it fell short of identifying a suitable drug target for therapy. ? The aberrant expression or splicing of metastasis genes conveys to primary cancers the ability to break through tissue barriers and disseminate. Established metastases differ from their original tumors by silencing genetic programs for extracellular matrix interactions and by activating genes associated with tissue remodeling and the oxidative metabolism. Cancer metastases to distinct target organs differ significantly in their gene expression profiles among each other and from the primary tumor. By contrast, metastases to the same target organ, derived from various primary tumors, share gene expression signatures. The results imply the possibility that chemotherapy of metastatic cancer may be more efficacious if selected to match the metastatic site affected rather than the organ of origin of the primary tumor. An advanced molecular treatment strategy for cancer will rely on the molecular definition of drug target, drug transport, and drug metabolism pharmacogenetics in the primary tumor. Consecutive to cancer dissemination, it will also require adjustments to account for the genetic changes in the metastases.
Georg F Weber attended medical school in Wuerzburg, Germany. He worked at the Dana-Farber Cancer Institute, Harvard Medical School from 1990 through 1999 and is currently on the faculty at the University of Cincinnati. Georg F Weber has published close to 90 scientific reports, including many in the most respected professional journals, and various monographs, most recently textbooks on molecular oncology and anti-cancer drugs. He holds several patents. As a component of his mission to research cancer dissemination, Georg F Weber is the founder and chief executive officer of MetaMol Theranostics, a company specialized in diagnosis and treatment of cancer metastasis
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version